STAT3 and pancreatic neoplasm: In conclusion, we describe the delivery of a STAT3 inhibitor, FLLL32, by liposomes (Figure 7A), which improves not only the bioavailability of FLLL32 but also the selective distribution of FLLL32 to pancreatic tumors.